MX2023002080A - Vector de poxviridae recombinante que expresa moleculas coestimuladoras. - Google Patents

Vector de poxviridae recombinante que expresa moleculas coestimuladoras.

Info

Publication number
MX2023002080A
MX2023002080A MX2023002080A MX2023002080A MX2023002080A MX 2023002080 A MX2023002080 A MX 2023002080A MX 2023002080 A MX2023002080 A MX 2023002080A MX 2023002080 A MX2023002080 A MX 2023002080A MX 2023002080 A MX2023002080 A MX 2023002080A
Authority
MX
Mexico
Prior art keywords
poxviridae
recombinant
vector expressing
stimulatory molecules
vector
Prior art date
Application number
MX2023002080A
Other languages
English (en)
Inventor
Ralf Amann
Melanie Mueller
Original Assignee
Prime Vector Tech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prime Vector Tech Gmbh filed Critical Prime Vector Tech Gmbh
Publication of MX2023002080A publication Critical patent/MX2023002080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

La presente invención se refiere a un vector de Poxviridae recombinante que expresa una molécula coestimuladora, una célula que contiene el vector de Poxviridae recombinante, una composición farmacéutica que contiene el vector de Poxviridae recombinante de acuerdo con la invención y/o la célula de acuerdo con la invención, y un método para el tratamiento de un ser vivo que necesita una vacunación con un antígeno.
MX2023002080A 2020-08-19 2021-08-16 Vector de poxviridae recombinante que expresa moleculas coestimuladoras. MX2023002080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20191751.5A EP3957322A1 (en) 2020-08-19 2020-08-19 Recombinant poxviridae vector expressing co-stimulatory molecules
PCT/EP2021/072759 WO2022038099A1 (en) 2020-08-19 2021-08-16 Recombinant poxviridae vector expressing co-stimulatory molecules

Publications (1)

Publication Number Publication Date
MX2023002080A true MX2023002080A (es) 2023-05-19

Family

ID=72148006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002080A MX2023002080A (es) 2020-08-19 2021-08-16 Vector de poxviridae recombinante que expresa moleculas coestimuladoras.

Country Status (13)

Country Link
US (1) US20230338516A1 (es)
EP (2) EP3957322A1 (es)
JP (1) JP2023539173A (es)
KR (1) KR20230050444A (es)
CN (1) CN116096408A (es)
AU (1) AU2021328653A1 (es)
BR (1) BR112023001294A2 (es)
CA (1) CA3185360A1 (es)
CL (1) CL2023000492A1 (es)
CO (1) CO2023002980A2 (es)
IL (1) IL299599A (es)
MX (1) MX2023002080A (es)
WO (1) WO2022038099A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023233007A1 (en) * 2022-06-02 2023-12-07 Eberhard Karls Universität Tübingen Medizinische Fakultät Sars-cov-2 vaccines and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892549A1 (en) * 2012-09-04 2015-07-15 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
DE102015111756A1 (de) 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor

Also Published As

Publication number Publication date
AU2021328653A8 (en) 2023-04-06
EP3957322A1 (en) 2022-02-23
BR112023001294A2 (pt) 2023-03-07
EP4153225A1 (en) 2023-03-29
CN116096408A (zh) 2023-05-09
CL2023000492A1 (es) 2023-10-30
KR20230050444A (ko) 2023-04-14
US20230338516A1 (en) 2023-10-26
CO2023002980A2 (es) 2023-06-20
AU2021328653A1 (en) 2023-03-09
IL299599A (en) 2023-03-01
WO2022038099A1 (en) 2022-02-24
CA3185360A1 (en) 2022-02-24
JP2023539173A (ja) 2023-09-13

Similar Documents

Publication Publication Date Title
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
SG10201907396XA (en) VARIANT RNAi
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
EP4253406A3 (en) Novel polypeptides and medical uses thereof
FI3778885T3 (fi) Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
CL2009001001A1 (es) Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares.
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
MX2023012888A (es) Metodos y composiciones para tratar un trastorno mediado por codon de terminacion prematura.
PH12020550117A1 (en) Variant rnai
PH12019502522A1 (en) Oncolytic virus and method
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
MX2023002080A (es) Vector de poxviridae recombinante que expresa moleculas coestimuladoras.
PH12020551955A1 (en) Anti-cd63 antibodies, conjugates, and uses thereof
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.